Overview

* Bicycle Therapeutics ( BCYC ) reports Q2 net loss of $79 mln compared to $39.8 mln a year earlier

* Company announces 30% cost realignment, primarily through workforce reduction

* Cash reserves at $721.5 mln, extending financial runway into 2028

Outlook

* Bicycle Therapeutics ( BCYC ) expects financial runway extended into 2028

* Company anticipates 30% operational savings through strategic cost realignment

* Bicycle plans FDA meeting for zelenectide pevedotin accelerated approval in Q4 2025

* Initial EphA2 human imaging data expected in 2H 2025

Result Drivers

* PIPELINE ADVANCEMENT - Increased R&D expenses driven by clinical program activities for zelenectide pevedotin in various cancers

* COST REALIGNMENT - Strategic cost realignment, including workforce reduction, to optimize operations and extend financial runway into 2028

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$78.95

Income mln

Q2 Basic -$1.14

EPS

Q2 $89.52

Operatin mln

g

Expenses

Q2 -$86.60

Operatin mln

g Incom

Q2 -$79.18

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Bicycle Therapeutics PLC ( BCYC ) is $24.50, about 69.6% above its August 7 closing price of $7.46

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)